Side Effects of Herceptin (Trastuzumab) and Perjeta (Pertuzumab)
The most common side effects when using Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy are diarrhea, alopecia (hair loss), neutropenia, nausea, fatigue, rash, and peripheral neuropathy, with diarrhea being particularly prominent and occurring in over 30% of patients. 1
Key Side Effects by Category
Gastrointestinal Effects (Most Prominent)
- Diarrhea is the hallmark side effect when pertuzumab is added to trastuzumab-based therapy, occurring significantly more frequently than with trastuzumab alone (ROR: 3.49) 2
- Nausea and vomiting are common, particularly in neoadjuvant and adjuvant settings 1
- Dyspepsia and general gastrointestinal issues occur regularly 3
Hematologic Effects
- Neutropenia is very common (>30% of patients) across all treatment settings 1
- Thrombocytopenia and anemia occur, especially with carboplatin-containing regimens 1
- Important note: neutropenia rates are not significantly increased by trastuzumab itself compared to chemotherapy alone 3
Dermatologic Effects
- Alopecia (hair loss) is extremely common (>30%) across all regimens 1
- Skin disorders including rash occur frequently, with increased risk when pertuzumab is added (ROR: 1.63) 2
- Pruritus (itching) shows increased incidence with pertuzumab addition (ROR: 1.96) 2
Neurologic Effects
- Peripheral neuropathy is common, particularly with taxane-containing regimens 1
- Paraesthesia and peripheral sensory neuropathy show significantly increased risk with pertuzumab addition (ROR: 2.60 and 5.94, respectively) 2
- Headache, dizziness, and vertigo occur regularly 3
Cardiac Effects (Critical to Monitor)
Pertuzumab increases the risk of clinical heart failure by approximately 2-fold (RR: 1.97) when added to trastuzumab 4. However, it does not significantly increase asymptomatic left ventricular dysfunction 4. Trastuzumab-associated cardiotoxicity includes:
- Congestive heart failure (0.4-16% depending on regimen) 5, 3
- Asymptomatic LVEF decline (7.1-18.6% in adjuvant trials) 5
- The risk is substantially higher when trastuzumab is given concurrently with anthracyclines (27% developed dysfunction, 16% had NYHA class III/IV heart failure) 5
Infusion-Related and Hypersensitivity Reactions
- Infusion-related reactions require monitoring during administration 1
- Hypersensitivity reactions including anaphylaxis can occur and require immediate discontinuation 1
- Fever and chills are common 3
Respiratory Effects
- Dyspnea (shortness of breath) occurs regularly 3, 6
- Cough and nasopharyngitis are common 3
- Nose bleeds occur 3
Infectious Complications
- Infections, particularly respiratory infections, show increased risk with pertuzumab addition (ROR: 1.54) 2
Constitutional Symptoms
- Fatigue and asthenia (weakness) are very common (>30%) 1, 3
- Myalgia (muscle pain) and back pain occur frequently 3
- Fever is common 3
Other Notable Effects
- Edema (limb/peripheral swelling) 3
- Increased lacrimation (tearing) 3
- Hypertension (10-15% experience grade 3-4) 6
- Insomnia 3
- Constipation 1
- Mucosal inflammation 1
- Dehydration 3
- Elevated liver enzymes (aspartate aminotransferase) 3
Critical Safety Considerations
Hospitalization Risk
Adding pertuzumab to trastuzumab increases the frequency of adverse events requiring hospitalization or prolonging hospital stays (ROR: 1.18) 2. This underscores the need for close monitoring and proactive management.
Thromboembolic Events
Thromboembolic events occurred in 10% of patients receiving pertuzumab plus trastuzumab plus metronomic chemotherapy in elderly/frail populations 6, highlighting increased vigilance needed in this demographic.
Age-Related Considerations
In older patients (≥70 years or ≥60 years with functional restrictions), the combination showed acceptable tolerability, though severe cardiac toxicities were occasionally observed, including fatal cardiac arrest and heart failure 6.
Clinical Monitoring Implications
The FDA label mandates monitoring for infusion reactions and hypersensitivity during administration 1. Based on historical adjuvant trial protocols, cardiac monitoring with LVEF assessment at baseline and every 3 months during trastuzumab treatment became standard practice 5, though the evidence supporting this specific interval as a quality metric has been questioned 5.
The addition of pertuzumab to trastuzumab-based therapy comprehensively alters the adverse event profile, particularly increasing gastrointestinal, dermatologic, neurologic, and infectious complications, while doubling the risk of clinical heart failure 2, 4.